Sunday, July 5, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary
Market Moves

The BCI category that motor and speech restoration overshadowed: Nia Therapeutics has FDA Breakthrough Designation for a preclinical brain implant for TBI-related memory loss

Nia Therapeutics, an Allston Massachusetts company co-founded in 2018 by University of Pennsylvania memory neuroscientist Michael Kahana and cognitive neuromodulation researcher Daniel Rizzuto, received FDA Breakthrough Device Designation on 13 March 2026 for its Smart Neurostimulation System (SNS), indicated for episodic memory loss in adults with prior moderate-to-severe traumatic brain injury. The SNS is a 60-channel wireless closed-loop cortical implant whose platform hardware was validated in a sheep study published in Brain Stimulation in December 2025. It is preclinical: no human implant yet, IDE application planned for 2026.

Jul 5, 2026 · 11 min read

Industry News

The first Canadian ALS patient in Neuralink's CAN-PRIME trial is also the first human anywhere to receive the implant via the new transdural surgical technique

Sgt Lee Marten of the Vancouver Police Department received a Neuralink N1 implant at Toronto Western Hospital on 20 May 2026, becoming the first Canadian ALS patient in the CAN-PRIME trial and the first human anywhere to receive the implant via Neuralink's new transdural surgical technique that preserves the dura rather than cutting it open. The story was broken by CBC News and MobiHealthNews on 2 July 2026.

Jul 4 · 7 min read

Policy & Regulation

China's NMPA has set a brain-computer interface classification framework: every implantable is Class III, and there is one narrow Class II lane

China's National Medical Products Administration issued Announcement No. 24 (2026) on 29 June 2026, releasing final Guiding Principles for the Classification and Definition of Brain-Computer Interface Medical Device Products plus a companion Generic Naming Guidelines. Every invasive BCI is Class III. Non-invasive BCIs are Class III by default. Non-invasive stroke-motor rehabilitation devices are Class II only if they do not incorporate artificial intelligence.

Jul 4 · 8 min read

Market Moves

Gestala closes US$62 million Angel+ round for ultrasound BCI, opens Shanghai NeuroAI headquarters

Gestala (格式塔科技), a Chinese non-invasive ultrasound brain-computer interface company led by founder and CEO Phoenix Peng, announced on 3 July 2026 that it had closed a US$62 million Angel+ financing round and formally opened a Shanghai NeuroAI headquarters. The company is the third Chinese ultrasound BCI startup to disclose funding within ten days, alongside Sisen Technology (1 July 2026) and Huachao Shenkong.

Jul 3 · 5 min read

Market Moves

The company behind the Argus II retinal implant is heading back to Nasdaq via reverse merger with ClearOne

Vivani Medical announced on 2 July 2026 an all-stock reverse-merger agreement to combine its Cortigent subsidiary with Nasdaq-listed ClearOne, forming Cortigent Holdings, Inc. under the expected ticker CRGT. Vivani will hold between 59.4 and 67.5 per cent of the combined company; the deal requires a concurrent 10 to 15 million dollar registered offering and is targeted to close in the third quarter of 2026.

Jul 2 · 7 min read

Research

An Imperial-Tsinghua BCI lets ten healthy people control a pair of extra robotic arms while balancing a ball with their own hands

Tianyu Jia and Dario Farina at Imperial College London, with collaborators at Tsinghua University and Southeast University Nanjing, published a Nature Communications paper on 2 July 2026 describing a tactile-encoded non-invasive BCI in which ten healthy participants controlled four supernumerary robotic degrees of freedom concurrently with a bimanual ball-balancing task, reaching 74.79 per cent single-task and 59.69 per cent dual-task online accuracy after three days of training.

Jul 2 · 8 min read